Les métamorphoses d'Ovide , traduites en prose françoise [par N. Renouard] et de nouveau... reveües... avec XV discours contenans l'explication morale et historique, de plus, outre le Jugement de Pâris, augmentées de la Métamorphose des abeilles traduite de Virgile, de quelques épistres d'Ovide et autres divers traités

[Les métamorphoses (français). 1619]

Castor et Pollux. Séjour de l'éternelle paix / Rameau, comp.. Iphigénie en Tauride. Unis dès la plus tendre enfance / Gluck, comp. ; Mons. Léon Beyle, T ; avec accompagnement d'orchestre

Titre uniforme : [Castor et Pollux. RCT 32A-B]. Extrait

Estats de l'Empire des Turqs en Europe, subdivisés suivant l'estendüe des Beglerbeglicz, ou Gouvernements dans lesquels sont marquées les résidences des Sangiacz qui en dépendent. ou sont encor la Transilvanie, la Valaquie, la Moldavie, la Petite Tartarie, &c. Tributaires des Turqs. Dressé sur les Memoires les plus Nouveaux / Par le Sr. Sanson, ... ; Dedié au roy ; Par... Hubert Iaillot, ... ; Cordier Sculpsit

Échelle(s) : [1:4 100 000 environ], Mille Pas Geometriques, ou Mille d'Italie 180 [= 8 cm]

Estats de l'Empire des Turqs en Europe, subdivisés suivant l'estendüe des Beglerbeglicz, ou Gouvernements dans lesquels sont marquées les résidences des Sangiacz qui en dépendent. ou sont encor la Transilvanie, la Valaquie, la Moldavie, la Petite Tartarie, &c. Tributaires des Turqs. Dressé sur les Memoires les plus Nouveaux / Par le Sr. Sanson, ... ; Dedié au roy ; Par... Hubert Iaillot, ... ; Cordier Sculpsit

Échelle(s) : [1:4 100 000 environ], Mille Pas Geometriques, ou Mille d'Italie 180 [= 8 cm]

The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.

Summary.  Hepatitis C viral (HCV) kinetics after initiation of interferon-based therapy provide valuable insights for understanding virus pathogenesis, evaluating treatment antiviral effectiveness and predicting treatment outcome. Adverse effects of liver fibrosis and steatosis on sustained virological response have been frequently reported, yet their impacts on the early viral kinetics remain unclear. In this study, associations between histology status and early viral kinetics were assessed in 149 HCV genotype 1-infected patients treated with pegylated interferon alfa-2a and ribavirin (DITTO trial). In multivariate analyses adjusted for critical factors such as IL28B genotype and baseline viral load, presence of significant fibrosis (Ishak stage > 2) was found to independently reduce the odds of achieving an initial reduction (calculated from day 0 to day 4) in HCV RNA of ≥2 logIU/mL (adjusted OR 0.03, P = 0.004) but was not associated with the second-phase slope of viral decline (calculated from day 8 to day 29). On the contrary, presence of liver steatosis was an independent risk factor for not having a rapid second-phase slope, that is, ≥0.3 logIU/mL/week (adjusted OR 0.22, P = 0.012) but was not associated with the first-phase decline. Viral kinetic modelling theory suggests that significant fibrosis primarily impairs the treatment antiviral effectiveness in blocking viral production by infected cells, whereas the presence of steatosis is associated with a lower net loss of infected cells. Further studies will be necessary to identify the biological mechanisms underlain by these findings.

Acvbp Versus Acvbp Plus Rituximab For Young Patients With Localized Low-Risk Diffuse Large B-Cell Lymphoma: A Study By The Groupe D'etude Des Lymphomes De L'adulte

Introduction: In a prior study, we demonstrated that ACVBP + consolidation was superior to 3 cycles of CHOP + radiotherapy in young patients (pts) with localized aggressive lymphoma (Reyes F et al. N Engl J Med 2005;352:1197). This randomized trial compared in these pts ACVBP vs. ACVBP + a short course of rituximab (R-ACVBP).Methods: untreated pts between 18 and 65y with stage I/II DLBCL and no adverse prognostic factors according to the aa-IPI were eligible. ACVBP consisted of 3 induction cycles given every 2 weeks: doxorubicin (75 mg/m2) day 1, cyclophosphamide (1.2g/m2) day 1, vindesine (2 mg/m2) day 1 and 5, bleomycin (10 mg) day 1 and 5, prednisone (60 mg/m2) day 1 to 5 followed by consolidation with metothrexate, ifosfamide, VP-16 and cytarabine. R-ACVBP consisted of the same regimen combined with 4 doses of rituximab (375 mg/m2) on day 1, 15, 29 and 43. Primary objective was EFS.Results: From 01/04 to 03/08, 223 pts were randomized, 113 in ACVBP and 110 in R-ACVBP arm. Characteristics were: median age 49y (18-65), stage I 63%, extranodal involvement 45%, bulky disease 4%. CR was 94% in ACVBP and 97% in ACVBP arm (ns). With a median follow-up of 43 months, the 3-y EFS was 82% (95% CI, 73% to 88%) in ACVBP and 93% (95% CI, 87% to 97%) in R-ACVBP group (P=0.0487). The 3-y PFS was 83% (95% CI, 74% to 89%) and 95% (95% CI, 89% to 98%) respectively (P=0.0205). OS did not significantly differ with a 3-y estimates of 97% (95% CI, 90% to 99%) for ACVBP and 98% (95% CI, 92% to 100%) for R-ACVBP (P=0.686). In multivariate analysis, a longer PFS was associated with R-ACVBP arm (P=0.0302) and lower b2-m level (P=0.0164). The same proportion of pts (27%) experienced at least 1 SAE in both groups. There were 4 deaths in each arm, with 1 treatment-related death in R-ACVBP (pneumocystis jiroveci pneumonia).Conclusion: the addition of only 4 doses of rituximab to ACVBP significantly improves EFS and PFS in younger pts with low-risk localized DLBCL.

Des prêtres et des cultes : toute prédication doit être réduite à la prononciation du précepte : "aimez Dieu plus que tout, et le prochain comme vous mêmes", "dans ces deux commandemens sont renfermés la loi et les prophètes" ([Reprod.])

Collection : Les archives de la Révolution française ; 8.1786